Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Kluk

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Biochimica Et Biophysica Acta|June 19, 2002
Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptorsMichael J Kluk, Timothy Hla
Surgical Pathology Clinics|August 16, 2016
Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Lymphoid NeoplasmsCaleb Ho, Michael J Kluk
The Journal of Molecular Diagnostics : JMD|October 23, 2018
Expedited Analysis and Reporting of Multiple Mutations that Modify Medical Management of Myeloid Malignancies: It's About (Turnaround) Time!Michael J Kluk, Adam Bagg
Surgical Pathology Clinics|May 6, 2023
Current Landscape of Ancillary Diagnostic Testing in Chronic Lymphocytic LeukemiaJulia T Geyer, Michael J Kluk
Ejhaem|September 2, 2022
A novel <i>SF3B1</i> variant in a patient with MDS with ring sideroblastsYahya A Al-Ghamdi, Michael J Kluk
Clinical Laboratory|December 18, 2020
Clinical Laboratory Validation and Implementation of Quantitative, Real-Time PCR-based Detection of NPM1 Type A MutationJoelle Racchumi, Wayne Tam, Michael J Kluk
Journal of Hematopathology|August 13, 2019
Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell LymphomasMustafa Al-Kawaaz, Teresa Sanchez, Michael J Kluk
Current Hematologic Malignancy Reports|June 5, 2020
NPM1 Biology in Myeloid NeoplasiaSanjay S Patel, Michael J Kluk, Olga K Weinberg
American Journal of Hematology|February 6, 2023
Acute hemolytic anemia after hematopoietic stem cell transplantation: An unusual invaderMohammad Alhomoud, Rosemary Soave, Michael J Kluk, et al.
Annals of Hematology|February 27, 2025
t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumabJulia T Geyer, Jia Ruan, Michael J Kluk, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Biochimica Et Biophysica Acta|June 19, 2002
Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptorsMichael J Kluk, Timothy Hla
Surgical Pathology Clinics|August 16, 2016
Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Lymphoid NeoplasmsCaleb Ho, Michael J Kluk
The Journal of Molecular Diagnostics : JMD|October 23, 2018
Expedited Analysis and Reporting of Multiple Mutations that Modify Medical Management of Myeloid Malignancies: It's About (Turnaround) Time!Michael J Kluk, Adam Bagg
Surgical Pathology Clinics|May 6, 2023
Current Landscape of Ancillary Diagnostic Testing in Chronic Lymphocytic LeukemiaJulia T Geyer, Michael J Kluk
Ejhaem|September 2, 2022
A novel <i>SF3B1</i> variant in a patient with MDS with ring sideroblastsYahya A Al-Ghamdi, Michael J Kluk
Clinical Laboratory|December 18, 2020
Clinical Laboratory Validation and Implementation of Quantitative, Real-Time PCR-based Detection of NPM1 Type A MutationJoelle Racchumi, Wayne Tam, Michael J Kluk
Journal of Hematopathology|August 13, 2019
Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell LymphomasMustafa Al-Kawaaz, Teresa Sanchez, Michael J Kluk
Current Hematologic Malignancy Reports|June 5, 2020
NPM1 Biology in Myeloid NeoplasiaSanjay S Patel, Michael J Kluk, Olga K Weinberg
American Journal of Hematology|February 6, 2023
Acute hemolytic anemia after hematopoietic stem cell transplantation: An unusual invaderMohammad Alhomoud, Rosemary Soave, Michael J Kluk, et al.
Annals of Hematology|February 27, 2025
t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumabJulia T Geyer, Jia Ruan, Michael J Kluk, et al.
Pageof 4